FDA Approval of Generic ARVs: Nevirapine and Combivir Now Off-Patent in the U.S.
Since the last issue of HTB, the U.S. Food and Drug Administration (FDA) has granted approval or tentative approval for the following new generic ARV products.
Full approval (**) indicates that these formulations can be marketed in the U.S. because the patent for the orginial drug has now expired.
Fixed Dose Combinations are reviewed for PEPFAR under the FDA guidance titled "Fixed Dose Combinations, Co-Packaged Drug Products, and Single-Entity Versions of Previously Approved Antiretrovirals for the Treatment of HIV."
This document was developed to clarify what regulatory requirements apply to such applications, what issues might be of concern, and how these issues should be addressed. The guidance is intended to encourage sponsors to submit applications for combination and co-packaged products, and to facilitate submission of such applications to FDA.
Effective patent dates are listed in the agency's publication titled "Approved Drug Products With Therapeutic Equivalence Evaluations," also known as the "Orange Book."
An updated list of generic tentative approvals (now at 140) is available on the FDA website.
The most notable developments this year have been the full license approvals that allows marketing in the U.S. for generic versions of nevirapine and the combined formulation of AZT/3TC.
Generic versions of AZT, 3TC and nevirapine are already used in some European countries. For nevirapine this includes Ireland, Spain and Portugal, although for reasons that are not clear, UK access is not expected until 2013.
Source: FDA list serve:
Links to external websites are current at time of posting but not maintained.
This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)